Company Overview and News

25
Prospect Capital's Dividend And NAV Sustainability Analysis - Part 2 (Including September-October 2018 Dividend Projection)

2018-06-18 seekingalpha
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX TRI NEWTL PBB

0
Gladstone Investment Corporation Announces Proxy Filing and Conference Call Date to Discuss Proxy Proposals

2018-06-15 globenewswire
MCLEAN, Va., June 15, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (the "Company") announced today that it plans to hold a conference call on Tuesday, June 26, 2018, at 9:00 am EDT to discuss the matters scheduled for a vote at this year's annual meeting of stockholders to be held on August 2, 2018. On Friday, June 15, 2018, the Company filed its proxy statement for the annual meeting of stockholders (the "Proxy Statement") with the U.
GAIN GAINM GADDP

0
GAIN / Gladstone Investment Corp. DEF 14A

2018-06-15 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
GAIN

25
TPG Specialty Lending's NAV Sustainability And Investment Rating Analysis (Post Q1 2018 Earnings)

2018-06-14 seekingalpha
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB

23
Main Street Capital's NAV, Dividend, And Valuation Compared To 14 BDC Peers (Post Q1 2018 Earnings) - Part 2

2018-06-12 seekingalpha
This article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB

25
TPG Specialty Lending's Dividend Sustainability Analysis (Includes Q3-Q4 2018 Dividend Projection)

2018-06-07 seekingalpha
Following multiple requests by readers, this article analyzes TSLX’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX NEWTL PBB

13
GAIN / Gladstone Investment Corp. N-2

2018-06-05 sec.gov
N-2 Table of Contents As filed with the Securities and Exchange Commission on June 5, 2018 1933 Act File No. 333-[ ]
GAIN

0
Gladstone Investment Corporation Exits its Investment in Drew Foam Companies, Inc.

2018-06-04 globenewswire
MCLEAN, Va., June 04, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (“Gladstone Investment”) announced today the sale of its equity interest and the prepayment of its debt investments in Drew Foam Companies, Inc. (“Drew Foam”) to a private equity firm. As a result of this transaction, Gladstone Investment realized a significant gain on its equity investment.
GAIN GAINM GADDP

23
Gladstone  Investment's Dividend Sustainability Analysis (Includes July-December 2018 Dividend Projection)

2018-06-01 seekingalpha
Following multiple requests, this article analyzes GAIN’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP MSCA TSLX NEWT MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB

0
GAIN / Gladstone Investment Corp. PRE 14A

2018-05-16 sec.gov
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2
GAIN

1
Gladstone Investment's (GAIN) CEO David Gladstone on Q4 2017 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Good day, ladies and gentlemen, and welcome to the Gladstone Investment Corporation Fourth Quarter and Year Ended 03/31/2018 Earnings Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] And as a reminder, this conference call is being recorded.
GAIN GAINM GADDP

6
GAIN / Gladstone Investment Corp. FORM 8-K (Current Report)

2018-05-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
GAIN

0
GAIN / Gladstone Investment Corp. FORM 8-K (Current Report)

2018-05-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
GAIN

26
Assessing Main Street Capital's Results For Q1 2018 (Includes Investment Rating Analysis)

2018-05-09 seekingalpha
This article assesses MAIN’s performance for Q1 2018 and compares results over the trailing twelve months.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX CVOVQ CVO NEWTL PBB

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to GAIN / Gladstone Investment Corp. on message board site Silicon Investor.

50% Gains Investing Airgain (AIRG)
Gain NeoStem (NBS) Subsidiary, PCT, gains NEW CLIENT
Shopping For The Ultimate Bargains USA Provokes Russia into War Against Georgia
Alexza(ALXA)-No Pain! Big Gain!!!!! ASYS -- Amtech Systems, 700% EPS gain?
EGHT takes off again Gaines Berland
CUSIP: 376546107